| Literature DB >> 26985372 |
Shashidhar Baikunje1, Mahesha Vankalakunti2, A Nikith3, A Srivatsa4, Suhan Alva4, Janardhan Kamath5.
Abstract
BACKGROUND: Crescent formation generally reflects severe glomerular injury. There is sparse literature on post-infectious glomerulonephritis (PIGN) with crescents in adults. This retrospective study looked at nine such cases to see if there is a correlation between the severity of presentation, steroid treatment, histological severity and outcome.Entities:
Keywords: crescents; infection-related glomerulonephritis; post-infectious glomerulonephritis; steroids; vasculitis
Year: 2016 PMID: 26985372 PMCID: PMC4792622 DOI: 10.1093/ckj/sfv147
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Clinical and laboratory characteristics at presentation
| Patient no. | Age (years) | Sex | Fever | Haematuria | Oliguria | Peripheral oedema | Other comorbidities | sCr (on admission) | sCr (peak) | eGFR on admission | Alb (g/L) | Proteinuria (g/day) | C3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 45 | M | Y | Y | Y | Y | HTN | 112.27 | 112.27 | 65.2 | 28 | 1.7 | Normal |
| 2 | 35 | F | Y | Y | Y | Y | – | 680.68 | 777.92 | 6.4 | 30 | – | Normal |
| 3 | 63 | F | N | Y | N | N | – | 327.08 | 554.27 | 13.2 | – | 2.3 | – |
| 4 | 65 | F | Y | Y | N | Y | Bronchiectasis | 247.52 | 724.88 | 18 | 30 | 1 | Normal |
| 5 | 45 | M | N | Y | Y | Y | HTN, alcoholism | 70.72 | 70.72 | 111.1 | 23 | 4.5 | Normal |
| 6 | 73 | M | N | Y | N | Y | IHD, chronic eczema | 770.85 | 770.85 | 6.4 | 32 | 2.5 | Normal |
| 7 | 35 | F | N | Y | Y | N | – | 466.75 | 539.24 | 9.8 | - | 3.6 | Low |
| 8 | 63 | M | Y | Y | Y | Y | – | 258.12 | 312.94 | 23.3 | 23 | 1.1 | – |
| 9 | 49 | F | Y | Y | Y | Y | – | 318.24 | 468.52 | 19.2 | 29 | – | Low |
Note: sCr is scaled in µmol/L; conversion factor for sCr in µmol/L to mg/dL, ÷ 88.4; eGFR (MDRD) is scaled in mL/min/1.73 m2; haematuria indicates macro-/microhaematuria or both.
M, male; F, female; Y, yes; N, no; HTN, hypertension; IHD, ischaemic heart disease; sCr, serum creatinine; eGFR, estimated glomerular filtration rate (MDRD); Alb, (serum) albumin; g/L conversion factor to g/dL, ÷10; C3, complement 3.
Site of infection and infectious agent
| Site of infection | Infectious agent |
|---|---|
| Urinary tract | |
| Acute gastroenteritis | – |
| Respiratory + urinary tract infection | |
| Leg cellulitis/skin | Positive ASO titre |
| Urinary tract | Alpha haemolytic |
| Urinary tract |
ASO, anti-streptolysin O.
Kidney biopsy characteristics
| Patient no. | Total no. of glomeruli | Glomeruli with crescents (%) | No. of globally sclerosed glomeruli | Tubular atrophy and interstitial fibrosis | Interstitial inflammation | Immunofluorescence |
|---|---|---|---|---|---|---|
| 1 | 13 | 11.76 | 0 | Nil | Nil | C3 3+, IgG 2+ |
| 2 | 4 | 50 | 1 | Nil | Nil | C3 3+ |
| 3 | 8 | 12.5 | 0 | Nil | Nil | C3 3+ |
| 4 | 20 | 25 | 0 | Nil | Nil | C3 3+, IgG 2+ |
| 5 | 12 | 33.33 | 0 | Nil | Nil | C3 3+ |
| 6 | 8 | 25 | 0 | Nil | Nil | C3 3+ |
| 7 | 5 | 100 | 0 | Mild | Minimal | C3 3+ |
| 8 | 8 | 50 | 0 | Nil | Nil | C3 3+ |
| 9 | 17 | 11.76 | 0 | Nil | Nil | C3 3+ |
C, complement; Ig, immunoglobulin.
Treatment and follow-up characteristics
| Patient no. | Steroids (route) | Antibiotics | ACEI/ARB | sCr (at last follow-up) | eGFR (at last follow-up) | Follow-up duration (months) |
|---|---|---|---|---|---|---|
| 1 | – | Y | Y | 114.92 | 60 | 3.33 |
| 2 | O | Y | Y | 61.88 | 99 | 41.75 |
| 3 | O | N | N | 68.95 | 79 | 3.5 |
| 4 | – | Y | N | 159.12 | 28 | 10 |
| 5 | – | Y | Y | 73.37 | 106 | 21.25 |
| 6 | – | N | N | 285.53 | 19 | 21 |
| 7 | IV>>O | Y | Y | 79.56 | 75 | 15 |
| 8 | O | Y | Y | 114.92 | 59 | 14.25 |
| 9 | IV>>O | Y | Y | 106.08 | 58 | 38.75 |
Note: sCr is scaled in µmol/L; conversion factor to mg/dL, ÷ 88.4; eGFR is scaled in mL/min/1.73 m2.
O, oral prednisolone; IV, intravenous methylprednisolone; Y, yes; N, no; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; sCr, serum creatinine; eGFR, estimated glomerular filtration rate (MDRD).